Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Commentary on the identity of fibroblast pneumocyte factor: rat vs. human.

  • Read more about Commentary on the identity of fibroblast pneumocyte factor: rat vs. human.

Effects of therapeutic hypothermia on white matter injury from murine neonatal hypoxia-ischemia.

  • Read more about Effects of therapeutic hypothermia on white matter injury from murine neonatal hypoxia-ischemia.

Bone mineral density in patients with inherited bone marrow failure syndromes.

  • Read more about Bone mineral density in patients with inherited bone marrow failure syndromes.

Pediatric Cushing disease: disparities in disease severity and outcomes in the Hispanic and African-American populations.

  • Read more about Pediatric Cushing disease: disparities in disease severity and outcomes in the Hispanic and African-American populations.

High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.

  • Read more about High-dose erythropoietin population pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.

Medical morbidities and DNA methylation of NR3C1 in preterm infants.

  • Read more about Medical morbidities and DNA methylation of NR3C1 in preterm infants.

Structural and genomic variation in preterm birth.

  • Read more about Structural and genomic variation in preterm birth.

Microarray gene expression analysis in ovine ductus arteriosus during fetal development and birth transition.

  • Read more about Microarray gene expression analysis in ovine ductus arteriosus during fetal development and birth transition.

Early postnatal docosahexaenoic acid levels and improved preterm brain development.

  • Read more about Early postnatal docosahexaenoic acid levels and improved preterm brain development.

Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.

  • Read more about Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y.

Pagination

  • Previous page ‹‹
  • Page 11
  • Next page ››
Subscribe to Pediatric research

Pediatrics Home

MAKE A GIFT

© 2022 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                              Accessibility  Privacy Policy  Terms of Use  A-Z Website List